Clicky

Rockwell Medical, Inc.(RMTI)

Description: Rockwell Medical, Inc. operates as an integrated biopharmaceutical company in the United States and internationally. The company offers products and services for the treatment of end-stage renal disease, chronic kidney disease (CKD), iron deficiency, secondary hyperparathyroidism, and hemodialysis (HD). Its products are used to cleanse patients' blood and replace nutrients lost during the kidney dialysis process. The company manufactures, sells, delivers, and distributes HD concentrates, such as CitraPure citric-acid concentrate, Dri-Sate dry acid, Renal Pure liquid acid concentrate, dry acid concentrate mixing system, RenalPure powder bicarbonate concentrate, and SteriLyte liquid bicarbonate concentrate; and ancillary products, including blood tubing, fistula needles, specialized custom kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers. It also intends to offer Calcitriol, a generic active vitamin D for the treatment of secondary hyperparathyroidism in dialysis patients. In addition, the company is also developing Soluble Ferric Pyrophosphate, which is in two Phase III clinical trials for iron therapy treatment in CKD-HD patients. Rockwell Medical, Inc. sells its products directly to hemodialysis providers, as well as through independent sales agents and distributors. The company was founded in 1995 and is based in Wixom, Michigan.


Keywords: Medicine Biopharmaceutical Clinical Medicine Acid Dialysis Phosphates Vitamins Kidney Disease Hemodialysis Membrane Technology Chronic Kidney Disease Thyroid Renal Disease Renal Dialysis End Stage Renal Disease Cleaning Agent Iron Deficiency Organ Failure Stage Renal Disease Hyperparathyroidism Secondary Hyperparathyroidism Kidney Dialysis Rockwell Medical Fistula Treatment Of End Stage Renal Disease

Home Page: www.rockwellmed.com

RMTI Technical Analysis

30142 South Wixom road
Wixom, MI 48393
United States
Phone: 248 960 9009


Officers

Name Title
Dr. Mark Strobeck Ph.D. Pres, CEO & Director
Mr. Paul E. McGarry SVP of Fin. & Chief Accounting Officer
Ms. Megan C. Timmins Sr. VP, Gen. Counsel & Corp. Sec.
Mr. James A. McCarthy Sr. VP of Bus. & Corp. Devel.
Mr. Timothy T. Chole Sr. VP of Sales & Marketing
Dr. Marc L. Hoffman M.D. Chief Medical Officer
Ms. Heather R. Hunter Sr. VP & Chief Corp. Affairs Officer
Mr. David J. Kull Sec.
Mr. Jason Finkelstein Investor Relations Representative

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.7425
Price-to-Sales TTM: 0.1724
IPO Date: 1998-01-27
Fiscal Year End: December
Full Time Employees: 300
Back to stocks